IL13RA2 and glioblastoma: In our study, we observed for the first time that the patients with over expressed IL-13Rα2 treated with TMZ chemotherapies had shorter overall survival time compared with the patients with IL-13Rα2 negative expression treated with TMZ, implicating that IL-13Rα2 mRNA expression is associated with GBM resistance to TMZ chemotherapy.